B Löwenberg, W L van Putten, L F Verdonck, A W Dekker, G C de Gast, R Willemze, F E Zwaan, J Abels, P Sonneveld, J van der Lelie
{"title":"Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study.","authors":"B Löwenberg, W L van Putten, L F Verdonck, A W Dekker, G C de Gast, R Willemze, F E Zwaan, J Abels, P Sonneveld, J van der Lelie","doi":"10.1007/978-3-642-74643-7_119","DOIUrl":null,"url":null,"abstract":"<p><p>We have prospectively compared the values of autologous BMT (auto-BMT) and allogeneic marrow transplantation (allo-BMT) in patients (age 15-60 years) with acute myeloid leukemia (AML) who attained complete remission (CR) following remission-induction therapy. In 90/117 cases CR was reached. In 32 of those complete responders auto-BMT was undertaken and in 21 eligible cases HLA-matched allo-BMT. AML relapse was the predominant cause of failure after auto-BMT (17/32). The incidence of relapse after allo-BMT was 6/21. Patients treated with auto-BMT and allo-BMT have an overall survival of 37% and 66% at 3 years posttransplant (P = 0.05). Survival of the nongrafted complete responders is less than 10%. Allo-BMT in adult patients with AML in first complete remission provides a superior outcome when directly compared with the results of auto-BMT.</p>","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"655-60"},"PeriodicalIF":0.0000,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematology and blood transfusion","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-642-74643-7_119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
Abstract
We have prospectively compared the values of autologous BMT (auto-BMT) and allogeneic marrow transplantation (allo-BMT) in patients (age 15-60 years) with acute myeloid leukemia (AML) who attained complete remission (CR) following remission-induction therapy. In 90/117 cases CR was reached. In 32 of those complete responders auto-BMT was undertaken and in 21 eligible cases HLA-matched allo-BMT. AML relapse was the predominant cause of failure after auto-BMT (17/32). The incidence of relapse after allo-BMT was 6/21. Patients treated with auto-BMT and allo-BMT have an overall survival of 37% and 66% at 3 years posttransplant (P = 0.05). Survival of the nongrafted complete responders is less than 10%. Allo-BMT in adult patients with AML in first complete remission provides a superior outcome when directly compared with the results of auto-BMT.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
